DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases - PubMed
12 hours ago
- #immunity
- #vaccine
- #nanotechnology
- DNA origami vaccine nanoparticles (DoriVac) enhance humoral and cellular immune responses to infectious diseases like SARS-CoV-2, HIV, and Ebola.
- DoriVac uses heptad repeat 2 peptides and CpG adjuvant at precise nanoscale spacing to induce neutralizing antibodies, Th1 CD4+ T cells, and CD8+ T cells in naive mice.
- Pre-clinical studies with lymph-node-on-a-chip systems show DoriVac induces promising immune responses in human cells when conjugated with antigenic peptides or proteins.
- DoriVac with full-length SARS-CoV-2 spike protein achieves immune responses comparable to mRNA vaccines while potentially reducing storage constraints.
- DoriVac is a versatile, modular vaccine platform capable of inducing both humoral and cellular immunities, with potential for future use.